- Current report filing (8-K)
22 Febrero 2011 - 4:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 22, 2011 (February 15, 2011)
KING PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Tennessee
(State or Other Jurisdiction
of Incorporation)
|
|
001-15875
(Commission
File Number)
|
|
54-1684963
(IRS Employer
Identification No.)
|
|
|
|
501 Fifth Street, Bristol, Tennessee
(Address of principal executive offices)
|
|
37620
(Zip Code)
|
(423) 989-8000
(Registrants telephone number, including area code)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
|
|
|
o
|
|
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
o
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
o
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
o
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
Item 5.02.
|
|
Departure of Directors or Certain Officers; Election of Directors; Appointment
of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On February 15, 2011, James W. Elrod, Chief Legal Officer and Assistant Secretary of
King Pharmaceuticals, Inc., concluded his employment with the company.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
KING PHARMACEUTICALS, INC.
|
|
|
By:
|
/s/ Brian A. Markison
|
|
|
|
Name:
|
Brian A. Markison
|
|
|
|
Title:
|
President and
Chief Executive Officer
|
|
|
Date: February 22, 2011
3
King (NYSE:KG)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
King (NYSE:KG)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
Real-Time news about King Pharmaceuticals, Inc. (New York Stock Exchange): 0 recent articles
Más de Artículos de Noticias